From 17c46b66477c2ece716274416c55eb2b62390ccd Mon Sep 17 00:00:00 2001 From: Emily de la Rua Date: Wed, 9 Oct 2024 17:49:50 -0400 Subject: [PATCH] Update development snapshot --- .../_snaps/development/tables-ADA-adat02.md | 24 +++++++++---------- 1 file changed, 12 insertions(+), 12 deletions(-) diff --git a/package/tests/testthat/_snaps/development/tables-ADA-adat02.md b/package/tests/testthat/_snaps/development/tables-ADA-adat02.md index 1034555a2d..49481c42bd 100644 --- a/package/tests/testthat/_snaps/development/tables-ADA-adat02.md +++ b/package/tests/testthat/_snaps/development/tables-ADA-adat02.md @@ -6,18 +6,18 @@ Summary of Patients with Treatment-Induced ADA, PK Population Protocol: A: Drug X Antibody - ————————————————————————————————————————————————————————————————————————————— - A: Drug X C: Combination - (N=134) (N=132) (N=0) - ————————————————————————————————————————————————————————————————————————————— - Post-baseline evaluable patients 134 132 266 - Treatment-induced ADA patients 0 0 64 (24.1%) - Treatment-induced ADA patients with - Transient ADA 0 0 0 - Persistent ADA 0 0 0 - Median time to onset of ADA (weeks) NA NA 0.1 - ADA titer range (min - max) NA NA NA - ————————————————————————————————————————————————————————————————————————————— + ————————————————————————————————————————————————————————————————— + A: Drug X C: Combination + (N=134) (N=132) + ————————————————————————————————————————————————————————————————— + Post-baseline evaluable patients 134 132 + Treatment-induced ADA patients 38 (28.4%) 26 (19.7%) + Treatment-induced ADA patients with + Transient ADA 0 0 + Persistent ADA 0 0 + Median time to onset of ADA (weeks) 0.1 0.1 + ADA titer range (min - max) NA NA + ————————————————————————————————————————————————————————————————— ADA = Anti-Drug Antibodies (is also referred to as ATA, or Anti-Therapeutic Antibodies)